Denis OSullivan
Overview
Explore the profile of Denis OSullivan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
622
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
James L, Hailey L, Suribhatla R, McGagh D, Amarnani R, Bundy C, et al.
Ther Adv Musculoskelet Dis
. 2024 Dec;
16:1759720X241295920.
PMID: 39717741
Background: Psoriatic arthritis (PsA) is a chronic inflammatory condition that can affect individuals of all ages. Patients may experience a range of physical and psychological issues. Objective: To examine the...
2.
FitzGerald O, Behrens F, Barton A, Bertheussen H, Boutouyrie-Dumont B, Coates L, et al.
Ther Adv Musculoskelet Dis
. 2023 Sep;
15:1759720X231192315.
PMID: 37694182
Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory...
3.
Hailey L, Howells L, Bundy C, Kirtley S, Martin S, OSullivan D, et al.
RMD Open
. 2023 Aug;
9(3).
PMID: 37652555
Objectives: In psoriatic arthritis (PsA), self-management is important for patient function and quality of life. Behaviour change can be difficult, patients could benefit from high-quality support to initiate change. Our...
4.
Hailey L, Amarnani R, Bundy C, McGagh D, James L, Kirtley S, et al.
Clin Ther
. 2023 Aug;
45(9):841-851.
PMID: 37541907
Purpose: Psoriatic arthritis (PsA) is a multisystem inflammatory disorder associated with significant mortality and morbidity, including functional impairment and psychological disability. Although evidence-based treatment recommendations are available for the use...
5.
Ng B, Jadon D, Behrens F, de Wit M, FitzGerald O, Gladman D, et al.
J Rheumatol
. 2023 Aug;
50(Suppl 2):61-65.
PMID: 37527862
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 annual meeting, the Collaborative Research Network (CRN) met to present updates on several projects. These included...
6.
Couto P, Molina S, OSullivan D, ONeill L, Lyness A, Rafiq Q
Biotechnol Lett
. 2023 May;
45(8):1013-1027.
PMID: 37227598
Bioactive materials interact with cells and modulate their characteristics which enable the generation of cell-based products with desired specifications. However, their evaluation and impact are often overlooked when establishing a...
7.
Jadon D, Corp N, van der Windt D, Coates L, Soriano E, Kavanaugh A, et al.
J Rheumatol
. 2022 Dec;
50(3):438-450.
PMID: 36455946
Objective: Several advanced therapies have been licensed across the related conditions of psoriatic arthritis (PsA), Crohn disease (CD), ulcerative colitis (UC), and noninfectious uveitis. We sought to summarize results from...
8.
Coates L, Soriano E, Corp N, Bertheussen H, Callis Duffin K, Campanholo C, et al.
Nat Rev Rheumatol
. 2022 Oct;
18(12):734.
PMID: 36216924
No abstract available.
9.
Madden D, ONolan D, Rampal N, Babu R, Camur C, Al Shakhs A, et al.
J Am Chem Soc
. 2022 Jul;
144(30):13729-13739.
PMID: 35876689
We are currently witnessing the dawn of hydrogen (H) economy, where H will soon become a primary fuel for heating, transportation, and long-distance and long-term energy storage. Among diverse possibilities,...
10.
Coates L, Soriano E, Corp N, Bertheussen H, Callis Duffin K, Campanholo C, et al.
Nat Rev Rheumatol
. 2022 Jun;
18(8):465-479.
PMID: 35761070
Since the second version of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015, therapeutic options for psoriatic arthritis (PsA) have...